This study suggests that ZT55 represents a new class of highly-selective, small-molecule therapeutic agents for the treatment of myeloproliferative neoplasms caused by the activating V617F mutation in JAK2. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.